Nabriva Therapeutics (NASDAQ:NBRV) Rating Lowered to Hold at BidaskClub

Nabriva Therapeutics (NASDAQ:NBRV) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Wednesday, March 27th, BidAskClub reports.

NBRV has been the subject of a number of other reports. Zacks Investment Research raised Nabriva Therapeutics from a “hold” rating to a “buy” rating and set a $2.25 target price for the company in a research report on Tuesday, February 5th. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Nabriva Therapeutics in a research note on Wednesday, March 13th. ValuEngine downgraded Nabriva Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. Finally, Northland Securities reissued a “buy” rating and set a $12.50 target price on shares of Nabriva Therapeutics in a research note on Tuesday, March 12th. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $9.37.

Shares of NASDAQ NBRV traded up $0.06 during trading hours on Wednesday, reaching $2.72. The stock had a trading volume of 644,099 shares, compared to its average volume of 1,194,310. The stock has a market cap of $1.90 billion, a PE ratio of -1.67 and a beta of 2.31. The company has a quick ratio of 6.11, a current ratio of 6.11 and a debt-to-equity ratio of 0.35. Nabriva Therapeutics has a fifty-two week low of $1.12 and a fifty-two week high of $6.05.

Nabriva Therapeutics (NASDAQ:NBRV) last announced its earnings results on Tuesday, March 12th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). The firm had revenue of $0.80 million during the quarter, compared to analyst estimates of $0.61 million. Nabriva Therapeutics had a negative net margin of 1,188.69% and a negative return on equity of 101.03%. Sell-side analysts anticipate that Nabriva Therapeutics will post -1.19 earnings per share for the current year.

A number of large investors have recently made changes to their positions in NBRV. Bank of America Corp DE boosted its stake in Nabriva Therapeutics by 4,353.6% in the second quarter. Bank of America Corp DE now owns 55,403 shares of the biotechnology company’s stock valued at $193,000 after acquiring an additional 54,159 shares during the period. JPMorgan Chase & Co. bought a new stake in shares of Nabriva Therapeutics in the 3rd quarter worth $431,000. BlackRock Inc. grew its position in Nabriva Therapeutics by 99.5% during the third quarter. BlackRock Inc. now owns 936,624 shares of the biotechnology company’s stock valued at $2,529,000 after buying an additional 467,119 shares during the period. FMR LLC bought a new position in Nabriva Therapeutics during the third quarter valued at about $810,000. Finally, Dimensional Fund Advisors LP grew its position in Nabriva Therapeutics by 74.5% during the third quarter. Dimensional Fund Advisors LP now owns 600,393 shares of the biotechnology company’s stock valued at $1,621,000 after buying an additional 256,332 shares during the period. Hedge funds and other institutional investors own 4.62% of the company’s stock.

About Nabriva Therapeutics

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.

Recommended Story: Cost of Debt

Analyst Recommendations for Nabriva Therapeutics (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.